China Wireless Comms (SVFC) 0.0011 $SVFC
IntelliCell BioSciences Adds Raymond Hill to Board of Directors
Marketwire - Thu Aug 21, 11:55AM CDT
IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company"
(OTCQB: SVFC), a regenerative medicine company utilizing adult autologous stromal vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it has added Mr. Raymond Hill to its Board of Directors.
IntelliCell BioSciences Added New Members to Management Team
Marketwire - Tue Aug 19, 11:27AM CDT
IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company" (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous stromal vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it has added Mr. Vincent S. Dugan as Director of National Sales and Mr. John Huber III as interim Chief Financial Officer. The focus being to strengthen the launch of the establishment of additional cellular labs, all being cGTP, FDA registered labs, in hospitals and ambulatory surgical centers across the country. IntelliCell will be responsible for training staff on site and will maintain Quality Assurance of all labs from our headquarters in New York.
IntelliCell BioSciences Complies With Court Order for Ironridge Settlement
Marketwire - Mon Aug 18, 1:57PM CDT
IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company" (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous stromal vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced that it received a motion from the Supreme Court of the State of New York County of New York dated May 1, 2014 granting its Motion and denying Ironridge's Cross-Motion and directed Intellicell to settle the Order. The Judge "ORDERED, that Ironridge's first-priority security interest under the Security Agreement dated as of May 31, 2012 shall continue until the earlier of (i) payment by Intellicell to Ironridge in immediately available funds of $91,912,42 or (ii) the receipt by Ironridge of the correct Stock Certificate having the tradable value of $91,912.42 in accordance with Section 12.4 of the Committed Equity Agreement." Pursuant to Judge Oing's Order, entered on June 27, 2014 Intellicell delivered to Ironridge's counsel, Richard Haddad, Esq. 53,568,400 common shares of Intellicell having a value of $91,912.42. And pursuant to the Order, Ironridge's security interest in Intellicell's assets has now been extinguished.
Ironridge Global IV, Ltd. Successfully Obtains Final Enforcement Order Against IntelliCell BioSciences, Inc.
ACCESSWIRE - Mon Aug 18, 8:07AM CDT
Los Angeles, CA / ACCESSWIRE / Aug 18, 2014 / Ironridge Global IV, Ltd. successfully obtained a final order against IntelliCell BioSciences, Inc. (SVFC) from the Supreme Court of the State of New York. The court order requires IntelliCell to deliver all free-trading shares of common stock owed to Ironridge Global, in addition to full payment of all principal and interest owed under its Convertible Promissory Note. The court also ordered that Ironridge's first-priority security interest over all assets of Intellicell would continue under its Security Agreement until IntelliCell fully complied with the court's orders.
IntelliCell BioSciences Files Pre-IND With FDA for Osteoarthritis Lead by Dr. James Andrews
Marketwire - Fri Aug 01, 12:54PM CDT
IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company" (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous stomovascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it has filed its pre-IND with the FDA for a clinical trial in osteoarthritis of the knee under an Investigational New Drug Application (IND). Dr. James Andrews, the legendary orthopedic surgeon will be the principal investigator for the study. inVentiv Health Clinical will serve as the Clinical Research Organization (CRO) for the conduction of this clinical trial in osteoarthritis of the knee in accordance of an Investigational New Drug.
Sports Illustrated References IntelliCell BioSciences Technology for Athletes
Marketwire - Thu Jul 31, 1:53PM CDT
IntelliCell Biosciences, Inc. ("IntelliCell" or the "Company" (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced that this week Sports Illustrated featured its cellular technology and gives credit to the inventor and IntelliCell CEO, Steven Victor, MD in the article "Stem Cell Treatment: Out from the Shadows, Onto the Cutting Edge". The article also features Dr. James Andrews and his notorious work with some of the most elite professional athletes in the sports industry. The company appreciates the experience and expertise that Dr. Andrews brings to the lineup.
IntelliCell BioSciences Announces That Dr. Steven Victor Was Thanked for His Work in Brain Trauma Research for Veterans
Marketwire - Thu Mar 27, 8:01AM CDT
IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company" (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that at the Stand For The Troops event in Washington, D.C. last Saturday, March 23, Major General John Batiste, US Army (Ret.) and Major Ben Richards, US Army (Ret.) the brain trauma veteran who received his purple heart, thanked our CEO, Steven Victor, MD for his help with brain trauma veterans.
IntelliCell BioSciences Announces That It Will Develop Investigational Clinical Protocol Studies for the Treatment of ALS With Dr. Manuel Trujillo
Marketwire - Mon Mar 24, 12:17PM CDT
IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company" (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it will be entering into a research collaboration with Dr. Manuel Trujillo, Clinical Psychiatry NYU Department of Psychiatry and Medical Director of the Amen Clinic, to use its unique approach to the harvest and use of autologous adipose derived stromal vascular fraction cells (SVFC) for clinical studies of ALS (Lou Gehrig's Disease).
IntelliCell BioSciences Announces It Will File an IND for Osteoarthritis of the Knee in Conjunction With the Andrews's Research and Educational Foundation
Marketwire - Mon Mar 17, 8:25AM CDT
IntelliCell Biosciences, Inc. ("IntelliCell" or the "Company" (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it has signed consulting agreements with Dr Adam Anz and Dr Josh Hackel of the Andrews's Research and Education Foundation (AREF) in Gulf Breeze, Florida. Intellicell will be filing an IND for the treatment of osteoarthritis of knee lead by Dr. James Andrews and conducted by Drs. Anz and Hackel for its Stromal Vascular Fraction Cells (SVFC).
IntelliCell BioSciences Joins Forces With Dr. James Andrews's Research and Educational Foundation
Marketwire - Wed Mar 12, 1:36PM CDT
IntelliCell Biosciences, Inc. ("IntelliCell" or the "Company" (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it has signed a license agreement with Dr. James Andrews's Research and Education Foundation (AREF) in Gulf Breeze, Florida for the installation of its cGTP Cellular Processing Lab for the manufacturing of Stromal Vascular Fraction Cells (SVFC).
IntelliCell BioSciences Raises Capital for Strategic Growth
Marketwire - Wed Mar 12, 12:59PM CDT
IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company" (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVFCs) derived from the blood vessels found in adipose tissue, announced today that it has closed on a round of financing from Yorkville Advisors, LLC.
Global Vending Machine Market 2014-2018
PR Newswire - Wed Jan 22, 9:29AM CST
Reportlinker.com announces that a new market research report is available in its catalogue:
IntelliCell Biosciences Announces it Has Received Notification That International Patents for Canada, Europe and Korea Are Filed and Pending Approvals
ACCESSWIRE - Thu Sep 19, 1:05PM CDT
NEW YORK, NY, September 19, 2013 - (ACCESSWIRE)- IntelliCell Biosciences, Inc. ("Company" (OTC Pink: SVFC) announced today that it has received notification that the Canadian Application, No. 2823123, Entitled: ULTRASONIC CAVITATION DERIVED STROMAL OR MESENCHYMAL VASCULAR EXTRACTS AND CELLS DERIVED THEREFROM OBTAINED FROM ADIPOSE TISSUE AND USED THEREOF has been filed.
OTC Signal Daily Stock Watch - IntelliCell BioSciences (OTC:SVFC)
WorldStockWire - Sun Sep 08, 8:30PM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
IntelliCell BioSciences Discusses their Stem Cell Treatment Technology in Online Interview
ACCESSWIRE - Fri Jul 12, 11:32AM CDT
NEW YORK, NY, July 12, 2013 - (eTeligis via ACCESSWIRE) IntelliCell BioSciences, Inc. (OTC PINK: SVFC), a developer of novel, patented stromal vascular fraction cells (stem cells) technologies that address the regenerative, curative and preventative conditions of disease states, announces an online interview where they discuss their current SVF (stem cell) treatment technology.
Maxim Group Issues Stem Cell Sector Report on IntelliCell BioSciences Based on Treatment Process
ACCESSWIRE - Mon Jul 08, 12:01PM CDT
NEW YORK, July 08, 2013 (eTeligis via ACCESSWIRE) -- IntelliCell BioSciences, Inc. (OTCPINK: SVFC), a developer of novel, patented technology used to isolate stromal vascular fraction cells (stem cells) from adipose (fat) tissue. These cells are used to address the regenerative, curative and preventative conditions of disease, announced New York based Maxim Group has issued a research opinion on stem cell sector, and our position within the industry.
IntelliCell BioSciences Announces That Dr Zain Khalpey Has Joined Its Advisory Board
ACCESSWIRE - Mon Jun 17, 10:41AM CDT
NEW YORK, NY June 17, 2013 / -- IntelliCell BioSciences, Inc. ("Company" (OTC PINK: SVFC) announced today that Dr Zain Khalpey, MD, PhD, MRCS (Eng) Director, Heart Transplant Program & Mechanical Circulatory Support, Division of Cardiothoracic Surgery?Associate Professor of Surgery, Physiological Sciences & Biomedical Engineering, University of Arizona College of Medicine has joined the Advisory Board.
IntelliCell BioSciences Announces That Its Cellular Tissue Laboratory was inspected by FDA
PR Newswire - Fri Jun 14, 11:40AM CDT
IntelliCell BioSciences, Inc. ("Company" (OTC Pink: SVFC) announced today that on May 14, 2013 through June 2, 2013, its cellular laboratory facility underwent a thorough inspection by the FDA. The observations from the FDA inspection were provided to the company in the Form 483. The Company will respond to those observations in a timely manner. IntelliCell will take the necessary actions to address the relevant FDA observations.
IntelliCell BioSciences Receives US Patent for its Stem Cell Extraction Technology
PR Newswire - Thu Jun 13, 11:53AM CDT
IntelliCell BioSciences, Inc. ("Company" (SVFC) announces that it has been notified by the US Patent office that its patent for stem cell extraction technology has been published. IntelliCell's proprietary patented method for deriving blood vessel originated vascular cells from adipose (fat) tissue by use of ultrasonic cavitation has been made official. This technology involves an innovative mechanical method for the separation of stromal vascular fraction cells from adipose (fat) tissue, without the use of enzymes. Vascular cells derived by IntelliCell's proprietary method are potentially useful in bringing the promise of regenerative medicine to many therapeutic and aesthetic procedures. Investors can access the published patent at the US Patent website by entering the patent # 8,440,440. Link to patent website: http://patft.uspto.gov/netahtml/PTO/srchnum.htm
IntelliCell BioSciences Adds Raymond Hill to Board of Directors
Marketwire - Thu Aug 21, 11:55AM CDT
IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company"
(OTCQB: SVFC), a regenerative medicine company utilizing adult autologous stromal vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it has added Mr. Raymond Hill to its Board of Directors. IntelliCell BioSciences Added New Members to Management Team
Marketwire - Tue Aug 19, 11:27AM CDT
IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company"
(OTCQB: SVFC), a regenerative medicine company utilizing adult autologous stromal vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it has added Mr. Vincent S. Dugan as Director of National Sales and Mr. John Huber III as interim Chief Financial Officer. The focus being to strengthen the launch of the establishment of additional cellular labs, all being cGTP, FDA registered labs, in hospitals and ambulatory surgical centers across the country. IntelliCell will be responsible for training staff on site and will maintain Quality Assurance of all labs from our headquarters in New York. IntelliCell BioSciences Complies With Court Order for Ironridge Settlement
Marketwire - Mon Aug 18, 1:57PM CDT
IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company"
(OTCQB: SVFC), a regenerative medicine company utilizing adult autologous stromal vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced that it received a motion from the Supreme Court of the State of New York County of New York dated May 1, 2014 granting its Motion and denying Ironridge's Cross-Motion and directed Intellicell to settle the Order. The Judge "ORDERED, that Ironridge's first-priority security interest under the Security Agreement dated as of May 31, 2012 shall continue until the earlier of (i) payment by Intellicell to Ironridge in immediately available funds of $91,912,42 or (ii) the receipt by Ironridge of the correct Stock Certificate having the tradable value of $91,912.42 in accordance with Section 12.4 of the Committed Equity Agreement." Pursuant to Judge Oing's Order, entered on June 27, 2014 Intellicell delivered to Ironridge's counsel, Richard Haddad, Esq. 53,568,400 common shares of Intellicell having a value of $91,912.42. And pursuant to the Order, Ironridge's security interest in Intellicell's assets has now been extinguished. Ironridge Global IV, Ltd. Successfully Obtains Final Enforcement Order Against IntelliCell BioSciences, Inc.
ACCESSWIRE - Mon Aug 18, 8:07AM CDT
Los Angeles, CA / ACCESSWIRE / Aug 18, 2014 / Ironridge Global IV, Ltd. successfully obtained a final order against IntelliCell BioSciences, Inc. (SVFC) from the Supreme Court of the State of New York. The court order requires IntelliCell to deliver all free-trading shares of common stock owed to Ironridge Global, in addition to full payment of all principal and interest owed under its Convertible Promissory Note. The court also ordered that Ironridge's first-priority security interest over all assets of Intellicell would continue under its Security Agreement until IntelliCell fully complied with the court's orders.
IntelliCell BioSciences Files Pre-IND With FDA for Osteoarthritis Lead by Dr. James Andrews
Marketwire - Fri Aug 01, 12:54PM CDT
IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company"
(OTCQB: SVFC), a regenerative medicine company utilizing adult autologous stomovascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it has filed its pre-IND with the FDA for a clinical trial in osteoarthritis of the knee under an Investigational New Drug Application (IND). Dr. James Andrews, the legendary orthopedic surgeon will be the principal investigator for the study. inVentiv Health Clinical will serve as the Clinical Research Organization (CRO) for the conduction of this clinical trial in osteoarthritis of the knee in accordance of an Investigational New Drug. Sports Illustrated References IntelliCell BioSciences Technology for Athletes
Marketwire - Thu Jul 31, 1:53PM CDT
IntelliCell Biosciences, Inc. ("IntelliCell" or the "Company"
(OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced that this week Sports Illustrated featured its cellular technology and gives credit to the inventor and IntelliCell CEO, Steven Victor, MD in the article "Stem Cell Treatment: Out from the Shadows, Onto the Cutting Edge". The article also features Dr. James Andrews and his notorious work with some of the most elite professional athletes in the sports industry. The company appreciates the experience and expertise that Dr. Andrews brings to the lineup. IntelliCell BioSciences Announces That Dr. Steven Victor Was Thanked for His Work in Brain Trauma Research for Veterans
Marketwire - Thu Mar 27, 8:01AM CDT
IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company"
(OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that at the Stand For The Troops event in Washington, D.C. last Saturday, March 23, Major General John Batiste, US Army (Ret.) and Major Ben Richards, US Army (Ret.) the brain trauma veteran who received his purple heart, thanked our CEO, Steven Victor, MD for his help with brain trauma veterans. IntelliCell BioSciences Announces That It Will Develop Investigational Clinical Protocol Studies for the Treatment of ALS With Dr. Manuel Trujillo
Marketwire - Mon Mar 24, 12:17PM CDT
IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company"
(OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it will be entering into a research collaboration with Dr. Manuel Trujillo, Clinical Psychiatry NYU Department of Psychiatry and Medical Director of the Amen Clinic, to use its unique approach to the harvest and use of autologous adipose derived stromal vascular fraction cells (SVFC) for clinical studies of ALS (Lou Gehrig's Disease). IntelliCell BioSciences Announces It Will File an IND for Osteoarthritis of the Knee in Conjunction With the Andrews's Research and Educational Foundation
Marketwire - Mon Mar 17, 8:25AM CDT
IntelliCell Biosciences, Inc. ("IntelliCell" or the "Company"
(OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it has signed consulting agreements with Dr Adam Anz and Dr Josh Hackel of the Andrews's Research and Education Foundation (AREF) in Gulf Breeze, Florida. Intellicell will be filing an IND for the treatment of osteoarthritis of knee lead by Dr. James Andrews and conducted by Drs. Anz and Hackel for its Stromal Vascular Fraction Cells (SVFC). IntelliCell BioSciences Joins Forces With Dr. James Andrews's Research and Educational Foundation
Marketwire - Wed Mar 12, 1:36PM CDT
IntelliCell Biosciences, Inc. ("IntelliCell" or the "Company"
(OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it has signed a license agreement with Dr. James Andrews's Research and Education Foundation (AREF) in Gulf Breeze, Florida for the installation of its cGTP Cellular Processing Lab for the manufacturing of Stromal Vascular Fraction Cells (SVFC). IntelliCell BioSciences Raises Capital for Strategic Growth
Marketwire - Wed Mar 12, 12:59PM CDT
IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company"
(OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVFCs) derived from the blood vessels found in adipose tissue, announced today that it has closed on a round of financing from Yorkville Advisors, LLC. Global Vending Machine Market 2014-2018
PR Newswire - Wed Jan 22, 9:29AM CST
Reportlinker.com announces that a new market research report is available in its catalogue:
IntelliCell Biosciences Announces it Has Received Notification That International Patents for Canada, Europe and Korea Are Filed and Pending Approvals
ACCESSWIRE - Thu Sep 19, 1:05PM CDT
NEW YORK, NY, September 19, 2013 - (ACCESSWIRE)- IntelliCell Biosciences, Inc. ("Company"
(OTC Pink: SVFC) announced today that it has received notification that the Canadian Application, No. 2823123, Entitled: ULTRASONIC CAVITATION DERIVED STROMAL OR MESENCHYMAL VASCULAR EXTRACTS AND CELLS DERIVED THEREFROM OBTAINED FROM ADIPOSE TISSUE AND USED THEREOF has been filed. OTC Signal Daily Stock Watch - IntelliCell BioSciences (OTC:SVFC)
WorldStockWire - Sun Sep 08, 8:30PM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
IntelliCell BioSciences Discusses their Stem Cell Treatment Technology in Online Interview
ACCESSWIRE - Fri Jul 12, 11:32AM CDT
NEW YORK, NY, July 12, 2013 - (eTeligis via ACCESSWIRE) IntelliCell BioSciences, Inc. (OTC PINK: SVFC), a developer of novel, patented stromal vascular fraction cells (stem cells) technologies that address the regenerative, curative and preventative conditions of disease states, announces an online interview where they discuss their current SVF (stem cell) treatment technology.
Maxim Group Issues Stem Cell Sector Report on IntelliCell BioSciences Based on Treatment Process
ACCESSWIRE - Mon Jul 08, 12:01PM CDT
NEW YORK, July 08, 2013 (eTeligis via ACCESSWIRE) -- IntelliCell BioSciences, Inc. (OTCPINK: SVFC), a developer of novel, patented technology used to isolate stromal vascular fraction cells (stem cells) from adipose (fat) tissue. These cells are used to address the regenerative, curative and preventative conditions of disease, announced New York based Maxim Group has issued a research opinion on stem cell sector, and our position within the industry.
IntelliCell BioSciences Announces That Dr Zain Khalpey Has Joined Its Advisory Board
ACCESSWIRE - Mon Jun 17, 10:41AM CDT
NEW YORK, NY June 17, 2013 / -- IntelliCell BioSciences, Inc. ("Company"
(OTC PINK: SVFC) announced today that Dr Zain Khalpey, MD, PhD, MRCS (Eng) Director, Heart Transplant Program & Mechanical Circulatory Support, Division of Cardiothoracic Surgery?Associate Professor of Surgery, Physiological Sciences & Biomedical Engineering, University of Arizona College of Medicine has joined the Advisory Board. IntelliCell BioSciences Announces That Its Cellular Tissue Laboratory was inspected by FDA
PR Newswire - Fri Jun 14, 11:40AM CDT
IntelliCell BioSciences, Inc. ("Company"
(OTC Pink: SVFC) announced today that on May 14, 2013 through June 2, 2013, its cellular laboratory facility underwent a thorough inspection by the FDA. The observations from the FDA inspection were provided to the company in the Form 483. The Company will respond to those observations in a timely manner. IntelliCell will take the necessary actions to address the relevant FDA observations. IntelliCell BioSciences Receives US Patent for its Stem Cell Extraction Technology
PR Newswire - Thu Jun 13, 11:53AM CDT
IntelliCell BioSciences, Inc. ("Company"
(SVFC) announces that it has been notified by the US Patent office that its patent for stem cell extraction technology has been published. IntelliCell's proprietary patented method for deriving blood vessel originated vascular cells from adipose (fat) tissue by use of ultrasonic cavitation has been made official. This technology involves an innovative mechanical method for the separation of stromal vascular fraction cells from adipose (fat) tissue, without the use of enzymes. Vascular cells derived by IntelliCell's proprietary method are potentially useful in bringing the promise of regenerative medicine to many therapeutic and aesthetic procedures. Investors can access the published patent at the US Patent website by entering the patent # 8,440,440. Link to patent website: http://patft.uspto.gov/netahtml/PTO/srchnum.htm 
